Category - Developments

Developments

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) reported positive results from an in vivo study of CRV431 in a diet-induced animal model of non-alcoholic fatty liver disease (DIAMOND). Hepion’s CRV431 administered orally and once...

March 23, 2021

Developments

Diabeloop, BIOCORP in personalized diabetes management pact

Diabeloop and BIOCORP (FR0012788065 – ALCOR) are collaborating to offer new, simple and personalized treatment options to people living with diabetes. BIOCORP has developed and markets Mallya, an intelligent sensor for...

March 22, 2021

Developments

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

Shanghai-based 111 Inc. (NASDAQ:YI) reported net revenue of $405.1-million (U.S.) in the fourth quarter of 2020, which was up 96.1%, from the year earlier quarter, beating its previous guidance of 81% to 90% growth. Net...

March 18, 2021

Developments

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

Hepion Pharmaceuticals (NASDAQ:HEPA) and ENDRA Life Sciences (NASDAQ:NDRA) signed a collaboration agreement to incorporate ENDRA’s Thermo Acoustic Enhanced UltraSound (TAEUS) as an add-on technology to support...

March 18, 2021

Developments

111, Inc. in strategic partnership with BeiGene

111, Inc. (NASDAQ:YI), a leading digital healthcare platform in China, entered into a strategic cooperation agreement with BeiGene (NASDAQ:BGNE; HKEX:06160), a commercial-stage and development biotechnology company...

March 17, 2021

Developments

111, Inc. achieves full distribution coverage across mainland China

111, Inc. (NASDAQ:YI) opened two new state-of-the-art, technology-driven fulfillment centers in the Northern cities of Xi’an and Shenyang, bringing the company’s total number of fulfillment centers to eight. The...

March 16, 2021

Developments

IntelGenx, atai Life Sciences in strategic pact; atai to purchase significant ownership stake

IntelGenx (TSXV:IGX; OTCQB:IGXT), a leader in pharmaceutical films, agreed to a strategic partnership with atai Life Sciences to develop treatments for mental health disorders. Under the accord, atai initially will...

March 15, 2021

Developments

Coridea, Deerfield to accelerate medtech innovation at NYC site

Coridea and Deerfield Management have established Deerfield Device Design and Development Catalyst to advance medtech innovation and accelerate the formation of commercial companies. Coridea is a medtech incubator;...

March 9, 2021

Developments

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

Closely-held Azura Ophthalmics of Israel announced positive topline results from a Phase 2 program evaluating the company’s investigational therapy for the treatment of Meibomian gland dysfunction (MGD). The company’s...

March 5, 2021

Developments

BriaCell Therapeutics closes $25-million public offering

BriaCell Therapeutics (TSXV:BCT; NASDAQ:BCTX, BCTXW) closed a U.S. offering of 4,852,353 units at a price of $4.25 a unit and 1,030,000 pre-funded units at a price of $4.24 a unit for gross proceeds of about $25-million...

February 26, 2021

Category - Developments

Hepion Pharma reports new positive nonclinical antifibrotic data with CRV431

Diabeloop, BIOCORP in personalized diabetes management pact

111 Inc. posts 96.1% jump in Q4 net revenue; beating guidance

Hepion Pharma, ENDRA Life Sciences to collaborate in Hepion’s NASH trial

111, Inc. in strategic partnership with BeiGene

111, Inc. achieves full distribution coverage across mainland China

IntelGenx, atai Life Sciences in strategic pact; atai to purchase significant ownership stake

Coridea, Deerfield to accelerate medtech innovation at NYC site

Azura Ophthalmics posts positive Phase 2 results in Meibomian gland dysfunction

BriaCell Therapeutics closes $25-million public offering

General

More